Who Is Eligible for Wegovy®? Full Criteria, Exceptions, and Next Steps

The FDA's Official Eligibility Criteria for Wegovy®

The FDA defines two adult eligibility pathways for Wegovy®, and one pediatric pathway. Meeting either adult pathway is sufficient for a prescription, provided no contraindications are present.

The criteria come directly from the Wegovy® prescribing information filed with the FDA and reviewed at approval in June 2021. Novo Nordisk's label states the approved population as: "as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition." [1]

Pathway 1: BMI 30 or Higher (Obesity)

A measured BMI at or above 30 kg/m² qualifies an adult patient without any additional conditions required. This threshold aligns with the standard clinical definition of obesity used by the CDC. [2]

BMI is calculated as weight in kilograms divided by height in meters squared. A 5-foot-9 adult weighing 204 pounds carries a BMI of approximately 30.1, which would meet this threshold. BMI is an imperfect tool, but it remains the metric written into the FDA label.

Pathway 2: BMI 27 or Higher Plus a Weight-Related Comorbidity

Adults with a BMI of 27 to 29.9 qualify if they have at least one of the following conditions documented in their medical record:

• Type 2 diabetes mellitus (diagnosed per ADA criteria: fasting glucose 126 mg/dL or higher on two occasions, or HbA1c 6.5% or higher) [3]
• Hypertension (systolic blood pressure 130 mmHg or higher, or diastolic 80 mmHg or higher, per the 2017 ACC/AHA guideline) [4]
• Dyslipidemia (LDL-C above goal, triglycerides 150 mg/dL or higher, or HDL-C below 40 mg/dL in men or 50 mg/dL in women)
• Obstructive sleep apnea (confirmed by polysomnography with AHI 5 or higher)
• Cardiovascular disease (established coronary artery disease, prior myocardial infarction, stroke, or peripheral artery disease)

The SELECT trial (N=17,604) specifically enrolled patients with established cardiovascular disease and BMI 27 or higher, and showed a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg vs. Placebo over a median of 39.8 months. This finding reinforced the comorbidity pathway's clinical rationale. [5]

Pediatric Eligibility (Ages 12 and Older)

The FDA extended Wegovy® approval to adolescents aged 12 and older in December 2022. The pediatric label requires a BMI at or above the 95th percentile for age and sex, which is the clinical definition of obesity in children and adolescents per the CDC growth charts. [6]

The STEP TEENS trial (N=201) demonstrated 16.1% mean reduction in BMI at 68 weeks with semaglutide 2.4 mg vs. A 0.6% reduction with placebo (P<0.001). [7] Prescribers apply the same contraindication checklist used in adults.

What the Phase 3 Trials Actually Showed About Eligible Patients

Understanding who responded to Wegovy® in the key trials helps frame real-world expectations for patients who meet eligibility criteria.

STEP-1: The Core Efficacy Data

STEP-1 (N=1,961) enrolled adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one comorbidity, excluding those with diabetes. At 68 weeks, semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight vs. 2.4% with placebo. [8] Roughly 86% of participants receiving semaglutide lost 5% or more of their body weight, and 50% lost 15% or more.

STEP-2: Patients With Type 2 Diabetes

STEP-2 (N=1,210) enrolled adults with type 2 diabetes and BMI 27 or higher. Mean weight loss at 68 weeks was 9.6% with semaglutide 2.4 mg vs. 3.4% with placebo. [9] Weight loss is attenuated in the setting of diabetes compared with non-diabetic participants, a pattern seen across GLP-1 receptor agonist trials.

STEP-3: Intensive Behavioral Intervention

STEP-3 (N=611) added an intensive behavioral intervention (low-calorie diet for 8 weeks, then group counseling) to semaglutide 2.4 mg. The combination produced 16.0% mean weight loss at 68 weeks. [10] This supports the FDA label language specifying Wegovy® as "an adjunct to a reduced-calorie diet and increased physical activity."

Absolute Contraindications: Who Cannot Use Wegovy®

Several groups are excluded from Wegovy® regardless of BMI.

Personal or Family History of Medullary Thyroid Carcinoma

Semaglutide caused dose-dependent thyroid C-cell tumors in rodent studies. The FDA label carries a Boxed Warning for this finding. [1] Humans with a personal history of medullary thyroid carcinoma (MTC), or a family history of MTC, must not use Wegovy®. The same restriction applies to patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The FDA notes that the human relevance of the rodent C-cell findings has not been established, but the boxed warning remains in place. Clinicians should ask specifically about thyroid cancer history and family history before prescribing.

Pregnancy

Wegovy® is contraindicated during pregnancy. Animal reproduction studies showed fetal harm at exposures lower than the human clinical dose. Women of reproductive potential should use effective contraception and discontinue Wegovy® at least two months before a planned pregnancy. [1]

Known Hypersensitivity

Patients with a prior serious hypersensitivity reaction to semaglutide or any excipient in the Wegovy® formulation are contraindicated. Serious reactions including anaphylaxis and angioedema have been reported in post-marketing surveillance. [1]

Important Warnings That May Affect Eligibility in Practice

Beyond absolute contraindications, several warnings require clinical judgment and may lead a prescribing physician to defer or decline Wegovy® for an otherwise eligible patient.

Pancreatitis History

Acute pancreatitis has been reported with GLP-1 receptor agonists. The Wegovy® label advises discontinuation if pancreatitis is confirmed and caution in patients with a history of pancreatitis. [1] A prescriber at Calibrate or any telehealth platform will typically ask about prior pancreatitis episodes during intake.

Diabetic Retinopathy

In SUSTAIN-6 (N=3,297, semaglutide 0.5 mg and 1.0 mg for cardiovascular outcomes), diabetic retinopathy complications occurred in 3.0% of the semaglutide group vs. 1.8% in the placebo group (hazard ratio 1.76, 95% CI 1.11 to 2.78). [11] Patients with type 2 diabetes and a history of diabetic retinopathy should have an ophthalmologic evaluation before starting Wegovy® and close monitoring during dose titration.

Gallbladder Disease

Rapid weight loss of any cause is a known risk factor for cholelithiasis. In STEP-1, cholecystitis occurred in 1.6% of semaglutide participants vs. 0.7% with placebo. [8] Patients with prior cholecystitis or known cholelithiasis should discuss this risk with their prescriber.

Heart Rate

Semaglutide increases resting heart rate by a mean of 1 to 4 beats per minute. In the SELECT trial population (high cardiovascular risk), the clinical significance remained modest. [5] Patients with symptomatic tachyarrhythmias or known sustained heart rate elevation may require cardiac evaluation before starting.

Lab Work and Workup Before Starting Wegovy®

No mandatory pre-treatment lab panel is written into the FDA label, but clinical practice and telehealth platform protocols typically include:

• HbA1c and fasting glucose to classify glycemic status and detect undiagnosed diabetes
• Thyroid-stimulating hormone (TSH) to rule out untreated hypothyroidism as a contributor to weight gain
• Lipid panel to document dyslipidemia as a qualifying comorbidity if BMI is 27 to 29.9
• Basic metabolic panel (renal function, electrolytes) given that gastrointestinal side effects can affect hydration
• Liver function tests if metabolic dysfunction-associated steatotic liver disease (MASLD) is suspected
• Serum calcitonin is not required by the label but is sometimes ordered in patients with thyroid nodules or family history concerns

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends assessing for secondary causes of obesity and comorbidities before initiating pharmacotherapy. [12]

How Calibrate and Other Telehealth Programs Determine Eligibility

Calibrate is a telehealth-based metabolic health program that pairs GLP-1 medications (including Wegovy® when available) with behavioral coaching across food, sleep, exercise, and emotional health. Their eligibility screening mirrors the FDA criteria but adds program-specific criteria.

Calibrate's Intake Process

Calibrate's intake asks patients to self-report height, weight, and existing diagnoses to generate a preliminary BMI assessment. A licensed physician then reviews the intake, orders labs if needed, and makes the final prescribing decision. Patients who meet FDA criteria but have a contraindication are declined or referred.

Calibrate has publicly stated that members must be 18 or older, meet the FDA BMI thresholds, and not have any of the listed contraindications. As of 2024, Calibrate also screens for medication coverage because Wegovy® carries a list price exceeding $1,300 per month without insurance. [13]

Insurance Coverage and Step Therapy

Many commercial insurance plans and Medicare Part D plans require step therapy before approving Wegovy®. This typically means documented failure of lifestyle intervention for a defined period (often 6 months) and sometimes prior use of a less expensive agent such as orlistat or phentermine/topiramate. A prescriber must document these steps for prior authorization.

The American Association of Clinical Endocrinology (AACE) 2016 obesity guidelines and their 2022 update support the use of GLP-1 receptor agonists as a first-line pharmacotherapy option for appropriate patients, which strengthens prior authorization arguments. [14]

Who Should Not Use Wegovy® Even If BMI Criteria Are Met

Certain clinical situations fall outside the absolute contraindications but typically lead a careful clinician to choose a different approach.

Type 1 Diabetes

Wegovy® is not approved for type 1 diabetes. The mechanism of GLP-1 receptor agonism is glucose-dependent insulin secretion, which does not correct the absolute insulin deficiency of type 1 diabetes. Off-label use carries risk of diabetic ketoacidosis if insulin dosing is not adjusted.

Severe Gastrointestinal Disease

Patients with gastroparesis, inflammatory bowel disease in active flare, or prior gastric surgery that alters absorption may not tolerate semaglutide's gastric-emptying effects. Nausea, vomiting, and diarrhea are the most common adverse events reported in STEP-1, occurring in 44%, 25%, and 30% of participants in the semaglutide group vs. 16%, 6%, and 16% with placebo, respectively. [8]

Active Eating Disorders

Clinical guidelines recommend against using weight-loss pharmacotherapy in patients with active anorexia nervosa or bulimia nervosa. The appetite-suppressing effect of semaglutide may worsen restrictive patterns or mask symptoms that require psychiatric treatment.

Pediatric Patients Under Age 12

The FDA approval for adolescents covers ages 12 and older only. There are no controlled efficacy or safety data in children under 12, and Wegovy® is not approved in this group.

Dose Titration and What Happens After You Start

Eligibility does not end at the prescription. The titration schedule affects tolerability and, for some patients, whether they can reach the therapeutic 2.4 mg maintenance dose.

The standard schedule from the Wegovy® label: [1]

| Weeks | Weekly Dose | |-------|-------------| | 1 to 4 | 0.25 mg | | 5 to 8 | 0.5 mg | | 9 to 12 | 1.0 mg | | 13 to 16 | 1.7 mg | | 17+ | 2.4 mg (maintenance) |

Patients who cannot tolerate dose escalation due to gastrointestinal side effects may remain at a lower dose for an additional 4 weeks before attempting the next increase. The label notes that if the 2.4 mg maintenance dose is not tolerated, discontinuation should be considered. Mean efficacy data from STEP-1 reflect patients who completed titration to 2.4 mg; patients remaining at lower doses may see less weight reduction.

Ongoing Eligibility: When Wegovy® Should Be Stopped

The FDA label specifies that Wegovy® should be discontinued if a patient has not lost at least 5% of baseline body weight after 16 weeks at the maintenance dose of 2.4 mg. Patients who do not meet this threshold are considered non-responders, and continued treatment is unlikely to produce meaningful benefit. [1]

The Endocrine Society guideline notes that "pharmacotherapy for obesity should be discontinued if a patient does not lose at least 5% of body weight after 12 weeks on the full dose." [12] This aligns with the Wegovy® label's built-in reassessment point.

Weight regain after stopping Wegovy® is substantial. In the STEP-4 trial (N=803), participants who discontinued semaglutide 2.4 mg at week 20 regained two-thirds of their lost weight by week 68, compared with continued weight loss in the group that continued the medication. [15] This evidence supports viewing Wegovy® as a chronic medication rather than a short-term course, which affects long-term eligibility planning and insurance coverage strategies.

Thyroid Considerations Specific to Wegovy® Eligibility

Because the Wegovy® boxed warning directly addresses thyroid C-cell tumors, thyroid history is one of the most common eligibility disqualifiers in clinical practice.

What the Boxed Warning Covers

The warning states: "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." [1] The FDA requires this warning because GLP-1 receptors are expressed on rodent thyroid C-cells.

Papillary and Follicular Thyroid Cancer

A history of papillary or follicular thyroid carcinoma (which originates from follicular cells, not C-cells) is not listed as a contraindication in the Wegovy® label. Prescribers typically consult the treating endocrinologist for these patients before initiating therapy.

Hypothyroidism and Eligibility

Treated, stable hypothyroidism is not a contraindication. Uncontrolled hypothyroidism should be addressed before starting Wegovy® because it independently contributes to weight gain and may blunt treatment response. TSH should be within the normal reference range (typically 0.5 to 4.5 mIU/L) before initiation.

A 2022 observational analysis in the Journal of Clinical Endocrinology and Metabolism found that patients with adequately treated hypothyroidism on levothyroxine achieved similar weight loss outcomes with GLP-1 receptor agonists compared with euthyroid patients. [16]